Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib + Cetuximab in mCRC
NCT04515394Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of tepotinib in colorectal cancer (CRC), sponsored by EMD Serono. Started Jan 2021; status: terminated.
02
Drugs
tepotinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04515394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515394.